Sugi Predict

Sugi Predict / Compounds / SCHEMBL1491787

SCHEMBL1491787

SCHEMBL1491787

Clc1ncc(Cl)c(Nc2ccccc2)n1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ BCL6 P41182 1/20 0.70
▸ PIN1 Q13526 3/20 0.60
▸ EGFR P00533 1/20 0.58
▸ JAK2 O60674 1/20 0.57
▸ LRRK2 Q5S007 1/20 0.57
▸ ALK Q9UM73 3/20 0.54
▸ CDK19 Q9BWU1 1/20 0.54
▸ CTSC P53634 3/20 0.52
▸ AURKA O14965 1/20 0.50
▸ NFKB1 P19838 1/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ CCNK O75909 1/20 0.46
▸ CCND3 P30281 1/20 0.46
▸ CDK9 P50750 1/20 0.46
▸ CDK6 Q00534 1/20 0.46
▸ IGF1R P08069 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29816634 0.84 JAK2 (0.79) BCL6JAK2LRRK2ALKCDK19
SCHEMBL15391316 0.84 JAK2 (0.79) BCL6JAK2LRRK2ALKCDK19
SCHEMBL2062387 0.83 CCNA2 (0.58) BCL6PIN1JAK2LRRK2ALK
SCHEMBL24654519 0.82 PIN1 (0.57) BCL6PIN1EGFRJAK2LRRK2
SCHEMBL4119766 0.82 AURKA (0.68) BCL6PIN1EGFRJAK2ALK
SCHEMBL1774193 0.82 IGF1R (0.68) BCL6PIN1EGFRALKCDK19
SCHEMBL4555643 0.82 PIN1 (0.61) BCL6PIN1EGFRJAK2LRRK2
SCHEMBL16684787 0.82 PIN1 (0.57) BCL6PIN1EGFRJAK2LRRK2
SCHEMBL5259406 0.82 PIN1 (0.57) BCL6PIN1EGFRJAK2LRRK2
SCHEMBL6642753 0.82 AURKA (0.51) BCL6PIN1EGFRJAK2LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122010851-A Phenyl ether-linked cyclohexylpyrimidine amine CDK12/13 inhibitor and preparation and application thereof 重庆医科大学 2026-05-12 — — CN disclosed
CN-119874626-A CDK12/13 inhibitor and application thereof 重庆医科大学 2025-04-25 — — CN disclosed
US-20240409609-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2024-12-12 — — US disclosed
CN-115448906-B 2-anilinopyrimidine derivative and preparation method and application thereof 深圳大学 2024-04-02 — — CN disclosed
WO-2023088385-A1 COMPOUND FOR DEGRADING EGFR PROTEIN AND USE THEREOF 浙江同源康医药股份有限公司 2023-05-25 — — WO disclosed
CN-111620852-B 5-chloro-pyrimidine-2, 4-diamine compound, and preparation method and application thereof 镇江植生源农业科技有限公司 2023-05-09 — — CN disclosed
WO-2023070114-A2 REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2023-04-27 — — WO disclosed
WO-2023070114-A2 REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2023-04-27 — — WO disclosed
CN-115448906-A 2-anilinopyrimidine derivative and preparation method and application thereof 深圳大学 2022-12-09 — — CN disclosed
US-20200317705-A1 PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. 2020-10-08 — — US disclosed
CN-1211373-C 2,4-di (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents ASTRAZENECA AB (SE) 2005-07-20 — — CN disclosed
EP-1140860-B1 PYRIMIDINE COMPOUNDS ASTRAZENECA AB (SE) 2004-09-22 — — EP disclosed
US-6649608-B2 Cyclin-dependent serine/threonine and focal adhesion kinase inhibitors ASTRAZENECA AB (SE) 2003-11-18 — — US disclosed
US-20030149266-A1 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents ASTRAZENECA AB (SE) 2003-08-07 — — US disclosed
US-6593326-B1 Useful as anti-cancer agents; and processes for their manufacture and pharmaceutical compositions containing them are described. Apoptotic effect in a warm-blooded animal such as man. ASTRAZENECA AB (SE) 2003-07-15 — — US disclosed
CN-1406230-A 2,4-di (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents ASTRAZENECA AB (SE) 2003-03-26 — — CN disclosed
EP-1268444-A1 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS AstraZeneca AB (SE) 2003-01-02 — — EP disclosed
EP-1140860-A1 PYRIMIDINE COMPOUNDS AstraZeneca AB (SE) 2001-10-10 — — EP disclosed
WO-2001064655-A1 2, 4-DI(HETERO-)ARYLAMINO (-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS ASTRAZENECA AB (SE) 2001-09-07 — — WO disclosed
WO-2000039101-A1 PYRIMIDINE COMPOUNDS ASTRAZENECA AB (SE) 2000-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149266-A1 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents CDK2, CCNI, CDK1 BCL6 633/4885PIN1 4044/4885EGFR 489/4885
US-20240409609-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF EGFR, ERBB2, ERBB3 BCL6 2454/4885PIN1 2060/4885EGFR 1/4885
US-20200317705-A1 PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS MAP3K6, PIK3CA, MAP3K20 BCL6 2239/4885PIN1 1111/4885EGFR 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.